This study identified classical monocytes to be associated with ER positive BC and with patient response to neoadjuvant endocrine treatment and cancer vaccination.
The immunological interventions were active immunotherapy Bacillus Calmette-Guérin (BCG) adoptive cell transfer (i.e. transfer factor (TF), tumour-infiltrating lymphocytes (TIL), dendritic cell/cytokine-induced killer (DC/CIK), antigen-specific cancer vaccines (melanoma-associated antigen 3 (MAGE-A3) and L-BLP25), and targeted natural killer (NK) cells...Two trials provided health-related quality of life results with contradicting results. AUTHORS' Based on this updated review, the current literature does not provide evidence that suggests a survival benefit from adding immunotherapy (excluding checkpoint inhibitors) to conventional curative surgery or radiotherapy, for people with localised NSCLC (stages I to III). Several ongoing trials with immune checkpoints inhibitors (PD-1/PD-L1) might bring new insights into the role of immunotherapy for people with stages I to III NSCLC.
Upfront docetaxel did not improve chemotherapy activity or tolerability; these results suggest that upfront neoadjuvant treatment with anthracyclines remains a valid option.
The eligible trials studied the following therapies: nivolumab (3 trials), pembrolizumab (1 trial), durvalumab (2 trials), atezolizumab (2 trials), avelumab (1 trial), PPV (3 trials), and tecemotide (2 trials). Recent evidence shows durability and limited toxicity of immune-based therapies in the treatment of advanced NSCLC. The majority of research has identified PD-1/PD-L1 immune-checkpoint inhibitors exhibiting favorable toxicity when compared to standard treatment. These modalities have also shown efficacy in NSCLC patients who have failed first-line treatment.
This cooperative group trial met its endpoint, demonstrating tolerability of bevacizumab + tecemotide after CRT and consolidation. In this selected group of patients, the median progression-free survival and overall survival are encouraging. Given that consolidation immunotherapy is now a standard of care following CRT in patients with LA-NSCLC, these results support a role for continued investigation of antiangiogenic and immunotherapy combinations in LA-NSCLC.